Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Struggles Could Determine Japanese iPS Cell Work

This article was originally published in PharmAsia News

Executive Summary

The future of Japanese research and development of induced pluripotent stem cells could be determined by a possible patent competition. Bayer Yakuhin, the Japanese subsidiary of German's Bayer AG, says its researchers created iPS cells from human cells before a Kyoto University team, which announced its "breakthrough" work last November. In addition to Japanese researchers, the University of Wisconsin also has claimed success in creating iPS cells from human cells at the same time as the Kyoto University team. (Click here for more - a subscription may be required

You may also be interested in...



US Probiotics Market Stirs With Chobani Beverages, Danone, Sofar And Plexus Blends For Kids

Chobani introduces Chobani Probiotic, its first functional probiotics beverage to support digestive and immune health; Danone North America extends its Danimals children’s yogurt line with products to support immune system; and Plexus Worldwide and Sofar Americas roll out children’s probiotics.

Social Media Posts Showed Almost 1,500 Adverse Events, 53 Deaths Linked To Essure: FDA Report

Report quantifies social media posts describing adverse events involving the Essure contraceptive device, which was pulled from the market amid safety concerns.

Cellular Biomedicine To Go Private In Consortium Buyout

Deal Snapshot: The China/US CAR-T firm will be bought out by its management team and institutional investors in a deal structured as a merger into a new company.

UsernamePublicRestriction

Register

LL1129788

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel